Eleftherios Spartalis1, Dimitrios I Athanasiadis2, Dimosthenis Chrysikos3, Michael Spartalis4, Georgios Boutzios5, Dimitrios Schizas6, Nikolaos Garmpis7, Christos Damaskos7, Stavroula A Paschou4, Argyrios Ioannidis4, Gerasimos Tsourouflis7, Dimitrios Dimitroulis7, Nikolaos I Nikiteas4,7. 1. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece eleftherios.spartalis@gmail.com. 2. 1st Department of Surgery, "Papageorgiou" General Hospital, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. University Department of Surgery, General and Oncologic Hospital of Kifissia 'Agii Anargiri', Athens, Greece. 4. Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 5. Endocrine Unit, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 6. 1st Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece. 7. 2nd Department of Propaedeutic Surgery, Medical School, National and Kapodistrian University of Athens Athens, Greece.
Abstract
BACKGROUND/AIM: Anaplastic thyroid cancer (ATC) is one of the most aggressive human malignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field. MATERIALS AND METHODS: This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI. RESULTS: Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC. CONCLUSION: HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs. Copyright
BACKGROUND/AIM: Anaplastic thyroid cancer (ATC) is one of the most aggressive humanmalignancies, remaining generally incurable. Histone deacetylase (HDAC) seems to play a role in regulating transcription of genes involved in ATC, making HDAC inhibitors (HDACI) promising anticancer drugs for ATC. The purpose of this review was to evaluate the role of HDACIs in ATC treatment and describe the latest trends of current research on this field. MATERIALS AND METHODS: This literature review was performed using the MEDLINE database. The keywords/phrases were; thyroid cancer, anaplastic, HDAC, histone, deacetylase*, HDACI. RESULTS: Compounds, such as SuberoylAnilide Hydroxamic Acid, valproic acid, sodium butyrate, butyrate, phenylbutyrate, trichostatin A, AB1-13, panobinostat or LBH589, belinostat, MS-275, depsipeptide, CUDC101, CUDC907, N-Hydroxy-7-(2-naphthylthio)-Hepanomide (HNHA), and PXD101 have shown promising antitumor effects against ATC. CONCLUSION: HDACIs represent a promising therapy for ATC management, both as monotherapy and in combination with other anticancer drugs. Copyright